網膜医薬品市場（2024年）：滲出型（ウエット型）加齢黄斑変性とその他の滲出性疾患

当レポートでは、世界の網膜医薬品市場について調査し、市場の概要とともに、滲出性網膜疾患に対する抗VEGF薬とその他の薬剤および薬剤候補に焦点を当て、糖尿病と視力を脅かす網膜疾患の有病率について最新の推定値を示しています。また、今後5年間の市場パフォーマンス予測、重要な将来動向、および市場に参入する企業40社の企業プロファイルなどを提供しています。

目次

• VEGF阻害剤
• その他の血管成長因子阻害薬
• 血漿カリクレイン阻害薬
• 遺伝子治療薬
• 細胞治療薬
• 抗炎症薬
• Wntシグナル伝達
• その他の作用機序

What's New:

The "2024 Retinal Pharmaceuticals Market Report: Wet AMD and Other Exudative Diseases" now focuses on anti-VEGFs and other drugs and drug candidates for exudative retinal diseases and gives updated estimates of the prevalence of diabetes and vision-threatening retinal diseases.

The new report analyzes treatment period trends and IVT injection shares by drug in the United States and Western Europe, reviews the cost per 30 days of wet AMD treatment in the United States, and evaluates more development-stage categories and companies.

The "2024 Retinal Pharmaceuticals Market Report: Wet AMD and Other Exudative Diseases" analyzes the market for anti-VEGFs and other drugs for the treatment of exudative retinal diseases. The report discusses important trends, analyzes key factors for future market success, examines the market's evolution, and forecasts growth over the next five years. Product demand is forecast in units and dollars, and market shares are analyzed by product category. Additionally, 40 competitors are profiled, with discussion of their products, strategic market position, background, and outlook.

Contents:

The report explores a variety of topics intended to provide depth and context to the understanding of market dynamics in this ophthalmic segment. Our coverage includes:

• Discussions of retinal diseases and their risk factors.
• Diagnosis and treatment of these diseases.
• A global view of retinal care and retina specialists.
• A review of pharmaceuticals and biologics for exudative retinal diseases in the marketplace.
• Analysis of investigational agents in the development pipeline.
• Profiles of companies developing and marketing pharmaceuticals for exudative retinal diseases, plus a listing of additional companies with preclinical programs.

The report provides market forecasts for branded ocular anti-VEGFs, cancer drugs used off label, and biosimilars used for the treatment of exudative retinal diseases. The report also includes a separate forecast for sustained-drug-delivery devices in the treatment of such diseases.

The report delves into the development pipelines of eight categories of retinal pharmaceuticals:

• VEGF inhibitors
• Other vascular growth factor inhibitors
• Plasma kallikrein inhibitors
• Gene therapies
• Cell therapies
• Anti-inflammatories
• Wnt signaling
• Other mechanisms of action